LogXp is a domain-specific AI application layer for biotech and pharmaceutical supply chains, built with the data, context, and reference standards of advanced therapy logistics. The platform spans six modalities — autologous and allogeneic ATMPs (advanced therapy medicinal products), radiopharmaceuticals, biologics, mRNA, and small molecules — across commercial, clinical, sample, and reference-standard networks and the full range of upstream and downstream materials. LogXp is engineered for regulatory compliance including 21 CFR Part 11 and GxP, with enterprise-grade data privacy and security.
LogXp is a precision supply chain intelligence platform for advanced therapies and biologics. The platform designs, qualifies, and orchestrates the supply lanes between every manufacturer and every patient — across small molecules, biologics, mRNA, radiopharmaceuticals, autologous ATMP (CAR-T and TIL therapy), and allogeneic ATMP (iPSC and off-the-shelf cell therapy).
NetXp, the first LogXp product, is in private beta. It enables pharma and biotech teams to design supply chain networks, qualify cold chains, author and e-sign Lane Risk Assessments, and score geopolitical, weather, customs, and courier risk per lane for any therapy modality. LogXp is built with 21 CFR Part 11 compliance, GxP validation, GAMP 5 categorization, and SOC 2 Type II security controls as core design requirements.
Key capabilities include supply chain network design, cold chain qualification and validation, Lane Risk Assessment authoring with electronic signature, an append-only 21 CFR Part 11 audit log, vein-to-vein chain of identity tracking for autologous cell therapy, AI-assisted supply chain intelligence with cited sources, radiopharmaceutical logistics with half-life and decay-to-dose tolerance modeling, mRNA ultra-cold chain management, and biologics cold chain network design.
LogXp is free for pre-revenue biotech organizations navigating complex supply chain models for advanced therapy medicinal products, covering only hosting, SLA, and any required customization. To get in touch, email [email protected].
Keywords: ATMP supply chain, cell and gene therapy logistics, CAR-T supply chain, vein-to-vein traceability, radiopharmaceutical logistics, mRNA cold chain, biologics supply chain, GxP supply chain software, 21 CFR Part 11, Lane Risk Assessment, advanced therapy supply chain, pharma supply chain intelligence, supply chain network design, advanced therapy medicinal products.
LogXp is complementary to cell and gene therapy orchestration platforms such as TrakCel, not a competitor. Where CGT orchestration systems manage the patient case and order journey, LogXp focuses on the upstream supply chain layer: designing supply networks, qualifying cold chains, authoring and e-signing Lane Risk Assessments, and scoring per-lane geopolitical and customs risk across small molecules, biologics, mRNA, radiopharmaceuticals, and ATMPs. The two layers work side by side, and LogXp is open to future partnerships and integrations with orchestration providers as customer interest develops.
Supply chain intelligence for the therapies that can't afford a broken link. More soon.